<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            William P Fay, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lawrence LK Leung, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer S Tirnauer, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 31, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The hemostatic system mediates clot formation (hemostasis) and clot breakdown (fibrinolysis):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemostasis
         </strong>
         – Most bleeding and clotting disorders are caused by abnormalities in hemostasis (dysfunction of platelets and/or clotting proteins). (See
         <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">
          "Overview of hemostasis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fibrinolysis
         </strong>
         – Less commonly, excessive bleeding or clotting can be caused by abnormalities in the fibrinolytic system. These disorders are the subject of this topic review.
        </p>
        <p>
        </p>
        <p>
         General discussions of causes of excess bleeding and excess clotting are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/1367.html" rel="external">
          "Approach to the adult with a suspected bleeding disorder"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1361.html" rel="external">
          "Overview of the causes of venous thrombosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          OVERVIEW OF THE FIBRINOLYTIC SYSTEM
         </span>
        </p>
        <p class="headingAnchor" id="H3946399923">
         <span class="h2">
          Fibrinolytic process
         </span>
         <span class="headingEndMark">
          —
         </span>
         The fibrinolytic system is essential for restoring blood vessel patency following clot formation. It also plays important roles in wound healing and tissue remodeling. The fibrinolytic system consists of proteolytic and regulatory factors.
        </p>
        <p>
         The key components are illustrated in  (
         <a class="graphic graphic_figure graphicRef81428" href="/z/d/graphic/81428.html" rel="external">
          figure 1
         </a>
         ) and include the following [
         <a href="#rid1">
          1,2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Proteases
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Plasmin, which cleaves fibrin
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Plasminogen, the precursor molecule (proenzyme) to plasmin
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Tissue-type plasminogen activator (tPA), the protease that cleaves plasminogen to plasmin
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Urokinase (also referred to as urinary-type plasminogen activator [uPA]), which also cleaves plasminogen to form plasmin
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inhibitors
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Plasminogen activator inhibitor 1 (PAI-1), the physiologic inhibitor of tPA and uPA
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Alpha-2-antiplasmin, the physiologic inhibitor of plasmin
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Thrombin-activatable fibrinolysis inhibitor (TAFI), a proenzyme that, upon activation, inhibits recruitment of plasminogen and tPA to the clot by removing C-terminal lysine residues from fibrin fragments, thereby slowing fibrinolysis
        </p>
        <p>
        </p>
        <p>
         Disorders affecting the abundance or function of these proteins can cause excess bleeding or thrombosis, with the clinical phenotype depending on which component is altered and whether its activity is increased or decreased.
        </p>
        <p>
         Changes that increase the activity of plasmin can result in bleeding disorders (see
         <a class="local">
          'Disorders with excess bleeding'
         </a>
         below), whereas those that decrease plasmin activity can result in thrombosis. (See
         <a class="local">
          'Thrombotic disorders'
         </a>
         below.)
        </p>
        <p>
         Plasmin has broad substrate specificity. It cleaves the polymerized fibrin strand at arginine and lysine residues, thereby producing fibrin degradation products (FDPs). Plasmin also cleaves fibrinogen and several other plasma proteins and clotting factors.
        </p>
        <p>
         One of the major FDPs is D-dimer, which consists of two D domains from adjacent fibrin monomers that have been crosslinked by activated factor XIII (FXIIIa). Since D-dimer is generated from cross-linked fibrin, but not from fibrinogen, an elevated plasma concentration of D-dimer indicates recent or ongoing intravascular blood coagulation [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1368.html" rel="external">
          "Clinical use of coagulation tests", section on 'Fibrin D-dimer'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2085943973">
         <span class="h2">
          Roles of specific proteins
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fibrinolytic proteins are summarized in the table  (
         <a class="graphic graphic_table graphicRef143854" href="/z/d/graphic/143854.html" rel="external">
          table 1
         </a>
         ) and discussed below.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h3">
          Plasminogen
         </span>
         <span class="headingEndMark">
          —
         </span>
         Plasminogen, the central zymogen of the fibrinolytic system, circulates in plasma at a concentration of approximately 2 microM. Plasminogen activators (see
         <a class="local">
          'tPA and uPA'
         </a>
         below) convert plasminogen to plasmin, a serine protease that degrades fibrin and other proteins.
        </p>
        <p>
         Plasmin activity is tightly regulated by control of its formation and by the plasmin inhibitor alpha-2-antiplasmin. (See
         <a class="local">
          'Alpha-2-antiplasmin'
         </a>
         below.)
        </p>
        <p>
         The plasminogen molecule contains specific lysine-binding sites, referred to as kringles, that mediate interactions with its targets (fibrin and plasminogen receptors) and major inhibitor (alpha-2-antiplasmin).
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h3">
          tPA and uPA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tissue-type plasminogen activator (tPA) and urinary-type plasminogen activator (uPA; urokinase) are the two main activators of plasminogen to plasmin.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          tPA
         </strong>
         – tPA is secreted by vascular endothelial cells and circulates in plasma in trace concentrations (typically below 10 ng/mL).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The primary role of tPA is to degrade intravascular fibrin by converting plasminogen to plasmin. Plasminogen binds to fibrin, which greatly accelerates its rate of activation by tPA. Therefore, tPA is a fibrin-specific plasminogen activator, which limits formation of plasmin in plasma and focuses its activity at sites of fibrin formation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Recombinant forms of tPA are used clinically as thrombolytic therapy for arterial and large venous thrombi. (See
         <a class="medical medical_review" href="/z/d/html/115775.html" rel="external">
          "Approach to reperfusion therapy for acute ischemic stroke"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8259.html" rel="external">
          "Approach to thrombolytic (fibrinolytic) therapy in acute pulmonary embolism: Patient selection and administration"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/55.html" rel="external">
          "Acute ST-elevation myocardial infarction: The use of fibrinolytic therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          uPA
         </strong>
         – uPA (urokinase) is secreted by a variety of cell types, including nonvascular cells.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Like tPA, uPA is present in low concentrations in plasma (typically 5 to 10 ng/mL), where it catalyzes plasmin formation and fibrinolysis. In contrast to tPA, uPA is not fibrin-specific. A more important role for uPA appears to be within the extravascular compartment, where it regulates fibrin accumulation within parenchyma and controls cell migration and function by binding to the uPA receptor (uPAR), which is expressed by many cell types [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Congenital deficiency of tPA or uPA has not been described in the medical literature, suggesting that complete deficiency of either of these factors may be lethal in utero. tPA and uPA are metabolized by the liver. Thus, severe liver disease can lead to increased circulating levels and increased bleeding risk. (See
         <a class="local">
          'Excess tPA or uPA'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/13932.html" rel="external">
          "Hemostatic abnormalities in patients with liver disease", section on 'Altered fibrinolytic system'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Alpha-2-antiplasmin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Alpha-2-antiplasmin (also referred to as alpha-2-plasmin inhibitor) is produced in the liver and is abundant in plasma (concentration, 1 microM), where it is the major physiologic inhibitor of plasmin [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         Although alpha-2-antiplasmin rapidly inactivates plasmin, it circulates at lower concentrations than plasminogen (2 microM). Therefore, intense plasminogen activation (eg, as occurs after administration of streptokinase, a non-fibrin-specific plasminogen activator purified from streptococci and used as a drug to lyse thrombi) can generate a concentration of plasmin exceeding that of alpha-2-antiplasmin, resulting in circulating free plasmin and a systemic fibrinolytic state.
        </p>
        <p class="headingAnchor" id="H1658346199">
         <span class="h3">
          PAI-1
         </span>
         <span class="headingEndMark">
          —
         </span>
         Plasminogen activator inhibitor-1 (PAI-1), encoded by the
         <em>
          SERPINE1
         </em>
         gene, is present in plasma in concentrations that usually range from 17 to 300 ng/mL [
         <a href="#rid6">
          6
         </a>
         ]. It is secreted by multiple cell types, including vascular endothelium, smooth muscle cells, hepatocytes, and adipocytes. Blood platelets contain PAI-1 and secrete it at sites of platelet activation.
        </p>
        <p>
         PAI-1 suppresses fibrinolysis by inhibiting tPA and uPA and in turn suppressing plasmin formation [
         <a href="#rid7">
          7-9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          TAFI
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thrombin activatable fibrinolysis inhibitor (TAFI) is a circulating procarboxypeptidase that is activated by thrombin, plasmin, or the thrombin-thrombomodulin complex. Activated TAFI cleaves C-terminal lysine and arginine residues from fibrin fragments (to which plasminogen and tPA bind with high affinity via their kringle domains), thereby disrupting recruitment of plasminogen and tPA to the partially digested fibrin clot, inhibiting fibrinolysis.
        </p>
        <p class="headingAnchor" id="H1643005179">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Congenital
         </strong>
         – Congenital disorders of fibrinolysis are very rare. The prevalence has not been defined, as publications of these abnormalities generally involve reports of isolated cases or extended pedigrees.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acquired
         </strong>
         – Acquired abnormalities of fibrinolysis are also rare and of undefined prevalence. However, these disorders are recognized to occur in specific clinical settings that are discussed below.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1753543652">
         <span class="h1">
          DISORDERS WITH EXCESS BLEEDING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Abnormal bleeding can result from fibrinogen deficiency/dysfunction or conditions that enhance fibrinolysis, either due to excessive plasminogen activation or deficiencies of fibrinolysis inhibitors.
        </p>
        <p>
         Evaluation and laboratory testing for these disorders is discussed below. (See
         <a class="local">
          'Evaluation for abnormal fibrinolysis'
         </a>
         below.)
        </p>
        <p>
         Fibrinogen deficiency and dysfunction are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1321.html" rel="external">
          "Disorders of fibrinogen"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Excess tPA or uPA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Congenital overexpression of tissue-type or urinary-type plasminogen activator (tPA or uPA), causing hyperfibrinolysis via excess activation of plasminogen to plasmin, is extremely rare, described only in case reports [
         <a href="#rid10">
          10-13
         </a>
         ].
        </p>
        <p>
         Acquired excesses in tPA or uPA can occur with chronic liver disease or the anhepatic period during orthotopic liver transplantation. The liver is responsible for metabolizing tPA and uPA, so decreased hepatic function can lead to a hyperfibrinolytic state due to decreased clearance of tPA from the circulation. (See
         <a class="medical medical_review" href="/z/d/html/13932.html" rel="external">
          "Hemostatic abnormalities in patients with liver disease", section on 'Altered fibrinolytic system'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13932.html" rel="external">
          "Hemostatic abnormalities in patients with liver disease", section on 'Bleeding'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Quebec platelet disorder
         </span>
         <span class="headingEndMark">
          —
         </span>
         Quebec platelet disorder (QPD), also called Quebec platelet syndrome (QPS), is a congenital platelet disorder in which excessive production of uPA within platelet alpha granules is responsible for increased bleeding risk [
         <a href="#rid14">
          14-18
         </a>
         ]. The condition is extremely rare, with an estimated prevalence of 1:220,000 in Quebec, Canada and 1:655,000 in Canada overall [
         <a href="#rid16">
          16
         </a>
         ]. Its prevalence worldwide is less. Inheritance is autosomal dominant with high penetrance. QPD is due to a tandem duplication of
         <em>
          PLAU
         </em>
         , the gene that encodes uPA [
         <a href="#rid19">
          19
         </a>
         ]. The duplicated copy of the
         <em>
          PLAU
         </em>
         gene is placed in a region of DNA controlled by a strong megakaryocyte-specific transcriptional enhancer, markedly increasing its expression [
         <a href="#rid20">
          20,21
         </a>
         ].
        </p>
        <p>
         The resulting platelets have high levels of uPA overexpression, which appears to inhibit normal hemostasis by several mechanisms:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Premature clot lysis
         </strong>
         – Overexpression of uPA and its release upon platelet activation contributes to premature lysis of thrombi. Studies of transgenic mice with platelet-specific overexpression of uPA suggest that premature clot lysis due to localized release of uPA from platelets is the predominant cause of bleeding [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Low platelet factor V
         </strong>
         – In individuals without QPD, approximately 20 percent of factor V in blood is carried within the alpha granules of platelets, with the balance in the plasma. During platelet activation, factor V and other active compounds carried in alpha granules are released, generating high local concentrations of these procoagulant factors within the forming clot.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Individuals with QPD have overexpression of uPA within platelet alpha granules.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The uPA activates plasminogen (which is also present within alpha granules) to plasmin, degrading intra-platelet stores of factor V and other hemostasis-related proteins, such as fibrinogen, producing a hemostatic abnormality [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Clinically, QPD is characterized by moderately severe bleeding that typically occurs 12 to 24 hours after surgery or trauma [
         <a href="#rid24">
          24
         </a>
         ]. In a questionnaire sent to members of a large extended kindred with QPD, bleeding into joints, bleeding longer than 24 hours after dental extraction or deep cuts, poor wound healing, heavy menstrual bleeding, spontaneous hematuria, and large bruises were commonly reported by affected relatives [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         On laboratory evaluation, mild thrombocytopenia is common. Platelet aggregation studies can be abnormal [
         <a href="#rid13">
          13
         </a>
         ]. Specialized laboratory testing, including analysis of platelet factor V, fibrinogen, and uPA, can be useful in establishing the diagnosis [
         <a href="#rid16">
          16
         </a>
         ]. Genetic testing can be used for diagnostic confirmation [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         Management may include administration of antifibrinolytic agents (
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          tranexamic acid
         </a>
         or
         <a class="drug drug_general" data-topicid="8561" href="/z/d/drug information/8561.html" rel="external">
          aminocaproic acid
         </a>
         ) at the time of bleeding or perioperatively [
         <a href="#rid26">
          26-28
         </a>
         ]. (See
         <a class="local">
          'Management'
         </a>
         below.)
        </p>
        <p>
         Platelet transfusion is not recommended, as it does not provide benefit.
        </p>
        <p class="headingAnchor" id="H2423138678">
         <span class="h2">
          Alpha-2-antiplasmin deficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Congenital deficiency of alpha-2-antiplasmin is a very rare bleeding disorder of undefined prevalence that results in enhanced plasmin activity and fibrinolysis [
         <a href="#rid29">
          29-31
         </a>
         ].
        </p>
        <p>
         Since the blood coagulation system and platelets function normally in individuals with alpha-2-antiplasmin deficiency, initial blood clotting after trauma is usually normal, with affected individuals typically presenting with delayed bleeding. Prolonged bleeding, mimicking hemophilia, can also occur.
        </p>
        <p>
         Bleeding after dental extraction and surgery are the most reported presentations. Multiple sites of bleeding have been observed, including epistaxis, gastrointestinal, and heavy menstrual bleeding, as well as intramedullary hematoma, an unusual form of bleeding.
        </p>
        <p>
         Homozygous (complete) deficiency of alpha-2-antiplasmin produces a more severe bleeding phenotype than heterozygous deficiency. A systematic literature review found 104 individuals with heterozygous deficiency, of which 63 percent were asymptomatic; however, severe bleeding with heterozygous deficiency of alpha-2-antiplasmin has been reported [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         Acquired alpha-2-antiplasmin deficiency has been reported with several disorders, including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Amyloidosis [
         <a href="#rid32">
          32
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe liver disease, which causes impaired synthesis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nephrotic syndrome, which causes increased renal excretion
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Disseminated intravascular coagulation (DIC), which causes increased consumption
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute promyelocytic leukemia [
         <a href="#rid33">
          33,34
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Malignancy [
         <a href="#rid34">
          34
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abdominal aortic aneurism [
         <a href="#rid34">
          34
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Head injury [
         <a href="#rid35">
          35
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Following thrombolytic therapy, which causes depletion [
         <a href="#rid36">
          36
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         Laboratory testing usually shows a shortened euglobulin clot lysis time. (See
         <a class="local">
          'Euglobulin clot lysis time (ECLT)'
         </a>
         below.)
        </p>
        <p>
         The diagnosis is established by measuring plasma levels of alpha-2-antiplasmin with either immunological or functional assays.
        </p>
        <p>
         Management of bleeding episodes and surgery may include plasma transfusion and/or oral antifibrinolytic agents (
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          tranexamic acid
         </a>
         or
         <a class="drug drug_general" data-topicid="8561" href="/z/d/drug information/8561.html" rel="external">
          aminocaproic acid
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          PAI-1 deficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Plasminogen activator inhibitor-1 (PAI-1) deficiency produces a hyperfibrinolytic state (deficiency of an inhibitor). Its prevalence is not defined, but it is very rare [
         <a href="#rid37">
          37-40
         </a>
         ].
        </p>
        <p>
         Only congenital forms have been described. Two studies reported a kindred with complete PAI-1 deficiency due to a small insertion within the
         <em>
          PAI1
         </em>
         gene that resulted in the production of a non-functional protein [
         <a href="#rid41">
          41,42
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Heterozygous individuals carrying only a single copy of the defective gene did not exhibit abnormal bleeding, even after surgery.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Homozygous deficient individuals exhibited delayed bleeding after surgery or trauma only, suggesting that their initial hemostatic response was normal, but their clots were lysed prematurely due to excessive fibrinolysis.
        </p>
        <p>
        </p>
        <p>
         A second study reported that complete PAI-1 deficiency due to a different mutation in the PAI-1 gene resulted in a severe bleeding disorder [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         Postoperative and post-traumatic bleeding are the most reported manifestations of PAI-1 deficiency. In women, heavy menstrual bleeding is common. Other reported findings include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Obstetric complications, including preterm labor and miscarriage, are prevalent, a distinguishing feature from other fibrinolysis-inhibitor deficiency states [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Delayed wound healing [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiac fibrosis [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Diagnosis of PAI-1 deficiency is challenging, as approximately 10 to 20 percent of healthy individuals with no history of abnormal bleeding have PAI-1 levels below the lower limit of detectability of commonly used commercial assays [
         <a href="#rid45">
          45,46
         </a>
         ].
        </p>
        <p>
         The euglobulin clot lysis time can be shortened but is sometimes normal. Qualitative deficiency of PAI-1 has been described [
         <a href="#rid39">
          39
         </a>
         ]. Therefore, measurement of both plasma PAI-1 antigen and activity is recommended if the diagnosis is suspected.
        </p>
        <p>
         Management includes antifibrinolytic agents (
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          tranexamic acid
         </a>
         or
         <a class="drug drug_general" data-topicid="8561" href="/z/d/drug information/8561.html" rel="external">
          aminocaproic acid
         </a>
         ), especially perioperatively or in patients undergoing dental procedures, as well as for women with heavy menstrual bleeding or other forms of gynecologic and obstetric bleeding [
         <a href="#rid42">
          42,47,48
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          TAFI deficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thrombin activatable fibrinolysis inhibitor (TAFI) is a procarboxypeptidase that circulates in an inactive form [
         <a href="#rid49">
          49
         </a>
         ]. TAFI is activated (TAFIa) by thrombin cleavage, which is greatly accelerated when thrombin is bound to its cofactor, thrombomodulin, on the endothelial cell surface. Plasmin can also activate TAFI [
         <a href="#rid50">
          50
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">
          "Overview of hemostasis", section on 'CPB2/TAFI'
         </a>
         .)
        </p>
        <p>
         TAFIa is a basic carboxypeptidase that cleaves C-terminal lysine residues from fibrin fragments generated during the initial stages of plasmin-mediated fibrinolysis. Since plasminogen and tPA bind to C-terminal lysines with high affinity, TAFIa disrupts recruitment of plasminogen and tPA to the partially digested fibrin clot, thereby inhibiting fibrinolysis  (
         <a class="graphic graphic_figure graphicRef81428" href="/z/d/graphic/81428.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
         TAFI deficiency could in theory produce a hemorrhagic defect.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Congenital TAFI deficiency has not been reported
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acquired TAFI deficiency with hyperfibrinolysis has been reported in patients with cirrhosis [
         <a href="#rid51">
          51
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         Enhanced fibrinolysis can also be a complication of coagulation factor deficiencies, such as in deficiencies of factor VIII, IX, or XI, due to decreased production of thrombin, and consequently a decreased activation of TAFI to TAFIa [
         <a href="#rid49">
          49,52-54
         </a>
         ].
        </p>
        <p>
         Therefore, decreased TAFI activation could contribute to the bleeding phenotype associated with coagulation factor deficiencies.
        </p>
        <p>
         Plasma TAFI concentration can be measured by immunoassays. However, such testing is generally not recommended in patients with undiagnosed bleeding disorders. Functional assays of TAFIa exist but are not commercially available and are generally not performed for clinical indications [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1118560291">
         <span class="h2">
          General hyperfibrinolytic states
         </span>
         <span class="headingEndMark">
          —
         </span>
         While single factor defects described above are rare, multifactorial hyperfibrinolysis and associated bleeding accompanied by activation of blood coagulation may be seen more commonly, especially in ill or hospitalized patients.
        </p>
        <p>
         As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          DIC
         </strong>
         – In disseminated intravascular coagulation (DIC), excessive fibrinolysis can be triggered by:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Release of tPA (from endothelial cells) or uPA (from cancer cells) [
         <a href="#rid55">
          55,56
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Depletion of alpha-2-antiplasmin
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These and other mechanisms are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1306.html" rel="external">
          "Evaluation and management of disseminated intravascular coagulation (DIC) in adults", section on 'Pathogenesis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thrombolytic therapy
         </strong>
         – Administration of a fibrin-specific plasminogen activator such as recombinantly produced tPA, or, more commonly, non-fibrin-specific plasminogen activator such as streptokinase or urokinase, can induce depletion of alpha-2-antiplasmin, plasminogen, and fibrinogen [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiopulmonary bypass
         </strong>
         – Bleeding is not uncommon after cardiopulmonary bypass. While multifactorial in etiology, activation of fibrinolysis can contribute to the bleeding diathesis. Use of antifibrinolytic agents in this setting can reduce perioperative blood loss. (See
         <a class="medical medical_review" href="/z/d/html/1627.html" rel="external">
          "Postoperative complications among patients undergoing cardiac surgery", section on 'Bleeding'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Heat stroke
         </strong>
         – Increased fibrinolysis with bleeding can occur in heat stroke and is typically accompanied by multiple coagulation abnormalities [
         <a href="#rid57">
          57,58
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/176.html" rel="external">
          "Severe nonexertional hyperthermia (classic heat stroke) in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6596.html" rel="external">
          "Heat stroke in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Postpartum hemorrhage
         </strong>
         – Most patients with postpartum hemorrhage (PPH) do not have hemostatic or fibrinolytic impairment. (See
         <a class="medical medical_review" href="/z/d/html/6710.html" rel="external">
          "Overview of postpartum hemorrhage", section on 'Causes of postpartum hemorrhage'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, a rare subgroup of patients with PPH exhibit a severe hyperfibrinolytic state, likely multifactorial in etiology, which has been termed acute obstetric coagulopathy and is characterized by massively elevated plasma concentrations of plasmin-antiplasmin complex (as much as 30-fold increased), increased D-dimer, hypofibrinogenemia/dysfibrinogenemia, decreases in factor V and factor VIII, and increased activated protein C [
         <a href="#rid59">
          59
         </a>
         ]. A similar hyperfibrinolytic coagulopathy can be seen rarely in patients with amniotic fluid embolism [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3101514129">
         <span class="h1">
          THROMBOTIC DISORDERS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Reduced fibrinolytic activity, due to a deficiency of plasminogen or its activators, or excessive expression of fibrinolysis inhibitors, can predispose to thrombosis.
        </p>
        <p class="headingAnchor" id="H1607079007">
         <span class="h2">
          Plasminogen deficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Congenital plasminogen deficiency is an autosomal recessive disorder caused by pathogenic variants in the
         <em>
          PLG
         </em>
         gene. The phenotype involves poor wound healing and formation of fibrin-rich pseudomembranes on the eyes (ligneous conjunctivitis) and other tissues. The bulk of the evidence suggests that plasminogen deficiency is not a risk factor for thrombosis. Details are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/132290.html" rel="external">
          "Plasminogen deficiency"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1777214624">
         <span class="h2">
          tPA or uPA deficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Documentation of a true deficiency of either tissue-type plasminogen activator (tPA) or urinary-type plasminogen activator (uPA; urokinase) is difficult, as these factors are normally present at very low concentration in the circulation. In addition, plasma levels of tPA or uPA may be affected by other factors, such as elevated levels of PAI-1.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Congenital tPA or uPA deficiency due to genetic causes (pathogenic variants in the
         <em>
          PLAT
         </em>
         or
         <em>
          PLAUR
         </em>
         genes, respectively) has not been described in the literature, suggesting that complete deficiency of these factors may be lethal in utero.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         tPA is released by vascular endothelial cells after transient venous occlusion or other provocations. There are rare case reports of defective tPA synthesis and/or release in patients with venous thrombosis. However, studies involving large series of patients with venous thrombosis failed to find an abnormality in provocable tPA release [
         <a href="#rid61">
          61,62
         </a>
         ]. There is no conclusive evidence that isolated tPA or uPA deficiency produces a thrombotic disorder in humans [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antibodies to tPA have been described in some patients with thrombosis secondary to the antiphospholipid syndrome (APS) [
         <a href="#rid63">
          63,64
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4667.html" rel="external">
          "Clinical manifestations of antiphospholipid syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Plasma tPA antigen and activity can be measured by immunologic (enzyme-linked immunosorbent assay [ELISA]-type) and functional assays, respectively. However, testing for tPA deficiency is rarely indicated for patients with undiagnosed thrombotic disorders.
        </p>
        <p class="headingAnchor" id="H2193567523">
         <span class="h2">
          PAI-1 overexpression
         </span>
         <span class="headingEndMark">
          —
         </span>
         Numerous studies have associated elevated plasma PAI-1 levels with thrombosis, both venous and arterial [
         <a href="#rid65">
          65
         </a>
         ]. Elevated PAI-1 has also been associated with septic shock and multiple organ system failure [
         <a href="#rid66">
          66-68
         </a>
         ].
        </p>
        <p>
         Selected examples of the association between PAI-1 overexpression and human diseases include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ischemic heart disease
         </strong>
         – Particular interest has been paid to the potential role of PAI-1 in the pathogenesis of coronary heart disease and myocardial infarction [
         <a href="#rid69">
          69
         </a>
         ]. As examples:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The European Concerted Action on Thrombosis and Disabilities Study prospectively followed 3043 patients with angina pectoris for two years and found that elevated baseline plasma levels of PAI-1 were associated with an increased incidence of myocardial infarction or sudden cardiac death [
         <a href="#rid70">
          70
         </a>
         ]. However, this association disappeared after correction for factors reflecting insulin resistance, such as obesity, body mass index, and serum triglyceride concentration.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         An analysis of the Framingham Heart Study offspring cohort, which included 3203 individuals without prior cardiovascular disease, revealed that elevated plasma PAI-1, assessed at baseline and after four years, was independently associated with development of cardiovascular disease (eg, myocardial infarction, prolonged angina pectoris, heart failure, and stroke) during an average follow-up period of 10 years [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A study using a Mendelian randomization approach and summary statistics from large genome-wide association studies (GWAS) suggested that enhanced PAI-1 expression has a causal effect on the development of coronary artery disease, possibly mediated by effects on glucose metabolism [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemolytic uremic syndrome
         </strong>
         – Increased levels of PAI-1 have been described in children with post-diarrheal hemolytic uremic syndrome (HUS); more severely affected patients had a higher plasma PAI-1 concentration, and normalization of plasma levels was correlated with an improvement in kidney function [
         <a href="#rid73">
          73
         </a>
         ]. However, a smaller study did not find that plasma PAI-1 levels were predictive of clinical outcome [
         <a href="#rid72">
          72
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6081.html" rel="external">
          "Clinical manifestations and diagnosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Venous thromboembolic disease
         </strong>
         – A polymorphism in the PAI-1 promoter (designated 4G/5G) may affect the risk of venous thromboembolic (VTE) disease when combined with other thrombophilic gene variants.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A 2014 meta-analysis found a slightly increased risk of unprovoked VTE in individuals with the 4G allele, which is associated with higher PAI-1 expression (odds ratio [OR] 1.3, 95% CI 1.1-1.5); this was further increased in individuals who also carried the factor V Leiden (FVL) mutation (OR 1.7, 95% CI 1.2-2.5) [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a 2015 analysis of a cohort of individuals from the Malmö Thrombophilia Study who had a prior VTE event, the factor V Leiden (FVL) variant plus the PAI-1 4G allele conferred a slightly increased risk of VTE recurrence compared with isolated FVL or 4G allele (hazard ratio [HR] 2.3, 95% CI 1.5-3.3) [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In prospective analyses of healthy general populations, one study found that elevated PAI-1 antigen was positively associated with future incident VTE [
         <a href="#rid76">
          76
         </a>
         ]. However, another study did not find this association [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In patients with pancreatic cancer, plasma concentration of active PAI-1 was positively associated with future risk of VTE [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Further studies are necessary to define the consequences of enhanced PAI-1 expression more precisely in humans.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4077759475">
         <span class="h2">
          TAFI overexpression
         </span>
         <span class="headingEndMark">
          —
         </span>
         Enhanced thrombin activatable fibrinolysis inhibitor (TAFI) expression is a potential risk factor for thrombosis, which is supported by the following clinical studies:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A report from the Leiden Thrombophilia Study found that elevated plasma levels of TAFI (&gt;90
         <sup>
          th
         </sup>
         percentile) were more common in patients with deep venous thrombosis (DVT) than in an age- and sex-matched control group, suggesting that elevated plasma TAFI was a risk factor for DVT (relative risk 1.7, 95% CI 1.1-2.5) [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of 600 patients with spontaneous (unprovoked) DVT who had completed at least three months of treatment with oral vitamin K antagonists (eg,
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         ), the relative risk of VTE recurrence was 1.7 (95% CI 1.1-2.7) among those with plasma TAFI levels ≥75
         <sup>
          th
         </sup>
         percentile compared with those having lower levels [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A study of 770 venous thrombosis patients and 743 healthy controls found that elevated plasma TAFI concentration was associated with increased risk of first venous thromboembolic event, even after unconditional logistic regression analysis was performed to adjust for potential confounding effects of age, sex, body mass index, and plasma levels of acute phase proteins such as fibrinogen and factor VIII [
         <a href="#rid81">
          81
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A case-control study found that functional plasma TAFI levels &gt;120 percent of normal were associated with an approximately sixfold increased risk of ischemic stroke [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         However, another study found that increased plasma TAFI was not associated with increased risk of either venous or arterial thrombosis in thrombophilic families [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3735034462">
         <span class="h2">
          Alpha-2-antiplasmin
         </span>
         <span class="headingEndMark">
          —
         </span>
         One study found that elevated alpha-2-antiplasmin levels were independently associated with increased risk of myocardial infarction [
         <a href="#rid84">
          84
         </a>
         ]. The Atherosclerosis Risk in Communities (ARIC) study found a modest, statistically significant association between alpha-2-antiplasmin plasma level and risk of ischemic stroke [
         <a href="#rid85">
          85
         </a>
         ]. However, after multivariate adjustment for other clinical variables, the hazard ratio no longer retained statistical significance.
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h2">
          Lipoprotein(a) increases
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lipoprotein(a) [Lp(a)] is a modified form of low-density lipoprotein (LDL) cholesterol that might be prothrombotic, mediated through effects on fibrinolytic proteins. Indications for Lp(a) testing and management implications are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4566.html" rel="external">
          "Lipoprotein(a)"
         </a>
         .)
        </p>
        <p>
         Lp(a) is composed of apoprotein(a) covalently linked by a single interchain disulfide bridge to apolipoprotein B-100. Apoprotein(a) contains a series of kringle domains, each of which contains a lysine-binding site. Kringles are also present in plasminogen and are responsible for its binding to fibrin and plasminogen receptors. Thus, Lp(a) can competitively inhibit binding of plasminogen to the fibrin clot and cell surfaces, inhibiting fibrinolysis and cell-associated plasmin formation.
        </p>
        <p>
         Evidence of a potential link between increased Lp(a) levels and arterial thrombosis includes the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A meta-analysis of prospective studies of plasma Lp(a) levels and the subsequent risk of acute coronary artery disease or death from coronary heart disease, stroke, or myocardial infarction found a positive correlation between Lp(a) and coronary heart disease [
         <a href="#rid86">
          86
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The Bruneck Study was a prospective, community-based investigation of atherosclerosis involving 826 adults in whom incident cardiovascular events were assessed prospectively over 15 years [
         <a href="#rid87">
          87
         </a>
         ]. There was a direct correlation between baseline Lp(a) levels and subsequent major adverse cardiovascular events, suggesting that plasma Lp(a) levels might be useful in risk stratification of individuals at intermediate cardiovascular risk based on standard clinical variables.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Two
         <em>
          LPA
         </em>
         variants have been identified that are strongly associated with an increased level of Lp(a) and an increased risk of coronary heart disease [
         <a href="#rid88">
          88
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Some organizations have advocated that measurement of plasma Lp(a) be considered in individuals with a 10-year risk of atherosclerotic cardiovascular events in the borderline range (5 to 7.4 percent) or intermediate (7.5 to 19.9 percent), with results being used to influence initiation of pharmacologic interventions, such as statins [
         <a href="#rid89">
          89
         </a>
         ].
        </p>
        <p>
         Venous thromboembolism (VTE) also has been associated with elevated plasma Lp(a) levels. One study of nearly 700 consecutive patients with VTE found that serum Lp(a) concentrations &gt;30 mg/dL were found in 20 percent of thrombosis patients, but in only 7 percent of healthy controls [
         <a href="#rid90">
          90
         </a>
         ]. This study, and a meta-analysis [
         <a href="#rid91">
          91
         </a>
         ], concluded that a plasma Lp(a) level &gt;30 mg/dL is an independent risk factor for VTE. Another meta-analysis of 14 published studies involving over 14,000 patients suggested that elevated plasma Lp(a) is significantly associated with VTE, though the difference in Lp(a) levels between VTE patients and controls was slight [
         <a href="#rid92">
          92
         </a>
         ]. In addition, an elevated Lp(a) level may promote the penetrance of other prothrombotic defects, such as the factor V Leiden mutation [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h1">
          EVALUATION FOR ABNORMAL FIBRINOLYSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         As noted above, congenital fibrinolytic abnormalities are rare, and acquired disorders of fibrinolysis are often multifactorial.
        </p>
        <p>
         Thus, for individuals with a negative family history of a fibrinolytic disorder, other evaluations for more common abnormalities are typically performed first, before proceeding to an evaluation for abnormal fibrinolysis.
        </p>
        <p class="headingAnchor" id="H2674362131">
         <span class="h2">
          Individuals with bleeding phenotypes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bleeding phenotypes may be caused by hyperfibrinolysis.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Primary hyperfibrinolytic states are rare and are due to excessive production of plasminogen activators or to decreased production of fibrinolysis inhibitors.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A secondary hyperfibrinolytic state with abnormal bleeding can develop in multiple clinical settings, including trauma, malignancy, liver transplantation or failure, and cardiopulmonary bypass [
         <a href="#rid93">
          93,94
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In an individual with abnormal bleeding, initial laboratory testing should assess for defects within the coagulation system or platelets. (See
         <a class="medical medical_review" href="/z/d/html/1367.html" rel="external">
          "Approach to the adult with a suspected bleeding disorder", section on 'Laboratory evaluation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5936.html" rel="external">
          "Approach to the child with bleeding symptoms", section on 'Diagnostic approach'
         </a>
         .)
        </p>
        <p>
         If a disorder of coagulation or platelets is not found and bleeding consistent with a fibrinolytic disorder is seen, a congenital or acquired defect of fibrinolysis should be considered. (See
         <a class="local">
          'Disorders with excess bleeding'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1367.html" rel="external">
          "Approach to the adult with a suspected bleeding disorder", section on 'Positive bleeding history and normal initial testing'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
         – Clinical history is essential in guiding whether and how to test for a fibrinolytic system disorder. The typical type of bleeding seen with fibrinolytic disorders includes the following [
         <a href="#rid13">
          13
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Delayed bleeding after trauma, surgery, or dental procedures
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Characteristic bleeding sites
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Mucocutaneous (epistaxis, dental)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Heavy menstrual bleeding
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Spinal cord
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Peri-umbilical
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pregnancy loss (miscarriage) and preterm birth, which are associated with PAI-1 deficiency [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Laboratory findings
         </strong>
         – Laboratory testing should be undertaken only after careful consideration, typically involving consultation with a hematologist or other expert in bleeding disorders. Specialized fibrinolytic system testing may be helpful in diagnosing hyperfibrinolysis. However, these tests can be expensive and are generally more technically challenging and less well standardized than coagulation assays. (See
         <a class="local">
          'Laboratory assays'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Typical laboratory findings in hyperfibrinolytic states include  (
         <a class="graphic graphic_table graphicRef143848" href="/z/d/graphic/143848.html" rel="external">
          table 2
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Complete blood count (CBC) and platelet count – Normal, unless there has been significant blood loss
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Prothrombin time (PT) and activated partial thromboplastin time (aPTT) – Normal or prolonged
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Fibrinogen – Low
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         D-dimer – Increased
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Euglobulin clot lysis time (ECLT) – Shortened
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Thromboelastography (TEG) – Increased clot lysis at 30 minutes (LY30)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Urea clot solubility (test for lack of fibrin cross-linking, as in factor XIII deficiency) – Normal
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The PT and aPTT are often prolonged in hyperfibrinolytic states; however, the sensitivity is low, and normal values do not exclude the diagnosis. The mechanism of prolongation involves degradation of fibrinogen and/or upstream coagulation factors.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Tests such as the euglobulin clot lysis time (ECLT) and thromboelastography (TEG) may be helpful in the evaluation, but they have not been demonstrated to be of value in predicting risk of recurrent bleeding [
         <a href="#rid96">
          96
         </a>
         ]. (See
         <a class="local">
          'Euglobulin clot lysis time (ECLT)'
         </a>
         below and
         <a class="local">
          'Thromboelastography (TEG) and ROTEM'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The diagnosis of a hyperfibrinolytic state depends on laboratory testing, medical history, and other clinical data; it cannot be made on laboratory testing alone. The observation of a beneficial clinical response to initiation of an antifibrinolytic drug can also help to establish a clinical diagnosis of hyperfibrinolysis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Importantly, the possibility of DIC must be eliminated before an antifibrinolytic agent can be safely initiated, as the use of antifibrinolytic agents in DIC can result in massive thromboses. (See
         <a class="medical medical_review" href="/z/d/html/1306.html" rel="external">
          "Evaluation and management of disseminated intravascular coagulation (DIC) in adults", section on 'Role of systemic therapies'
         </a>
         and
         <a class="local">
          'Therapies for hyperfibrinolytic states'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – The differential diagnosis of fibrinolytic disorders associated with excess bleeding includes:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          von Willebrand disease (VWD)
         </strong>
         – An inherited disorder of von Willebrand factor, which forms an adhesive bridge between platelets and sites of vascular injury; severe cases also have low factor VIII levels.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Factor XIII deficiency
         </strong>
         – A bleeding disorder mediated by loss of fibrin-fibrin crosslinking and fibrin-alpha-2-antiplasmin crosslinking.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Disseminated intravascular coagulation (DIC)
         </strong>
         – A disorder of intravascular clotting and fibrinolysis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Liver disease
         </strong>
         – Various disorders in which multiple hemostatic and fibrinolytic regulators are altered due to reduced hepatic synthesis or metabolism.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Individuals with VWD and factor XIII deficiency are otherwise well except for the bleeding disorder. VWD is common and is typically tested for early in the evaluation. Factor XIII deficiency is rare and associated with decreased plasma factor XIII activity and/or an abnormal urea clot solubility test. Evaluation for these disorders is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1307.html" rel="external">
          "Clinical presentation and diagnosis of von Willebrand disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1336.html" rel="external">
          "Rare inherited coagulation disorders", section on 'Diagnostic evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Individuals with DIC or severe liver disease generally are ill from their underlying condition. (See
         <a class="medical medical_review" href="/z/d/html/5915.html" rel="external">
          "Disseminated intravascular coagulation in infants and children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1306.html" rel="external">
          "Evaluation and management of disseminated intravascular coagulation (DIC) in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The table summarizes differences in laboratory testing in fibrinolytic disorders and DIC  (
         <a class="graphic graphic_table graphicRef78455" href="/z/d/graphic/78455.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2101213827">
         <span class="h2">
          Individuals with thrombotic phenotypes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thrombotic phenotypes may be caused by hypofibrinolysis. This may be due to underexpression of a plasminogen activator (tissue-type plasminogen activator [tPA] or urinary-type plasminogen activator [uPA]), or overexpression of a fibrinolysis inhibitor, including plasminogen activator inhibitor 1 (PAI-1), alpha-2-antiplasmin, or thrombin activatable fibrinolysis inhibitor (TAFI). (See
         <a class="local">
          'Thrombotic disorders'
         </a>
         above.)
        </p>
        <p>
         If laboratory evaluation is pursued to determine if a prothrombotic state is present, initial testing usually focuses on disorders associated with excessive thrombin activity, such as a hereditary thrombophilia or more common acquired conditions associated with increased thrombotic risk. (See
         <a class="medical medical_review" href="/z/d/html/1361.html" rel="external">
          "Overview of the causes of venous thrombosis"
         </a>
         .)
        </p>
        <p>
         Evaluation for hypofibrinolysis typically is pursued only if there is a strong thrombotic phenotype (recurrent or highly atypical thrombosis) and other evaluations were unrevealing, there is a strong, unexplained familial thrombophilia, or an individual presents with ligneous conjunctivitis, suggestive of plasminogen deficiency. (See
         <a class="local">
          'Plasminogen deficiency'
         </a>
         above.)
        </p>
        <p>
         Laboratory-based diagnosis of a hypofibrinolytic state can be difficult:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Levels of plasminogen activators in plasma are very low under normal conditions, making definitive diagnosis of abnormally low levels difficult. Measurement of plasma tPA and uPA is generally not indicated in patients with unexplained thrombosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The range for plasma levels of fibrinolysis inhibitors such as PAI-1 can vary widely among healthy individuals. This variability complicates establishing elevated plasma levels of a fibrinolysis inhibitor as the definitive cause of thrombosis in an individual patient.
        </p>
        <p>
        </p>
        <p>
         Laboratory testing may reveal a prolonged ECLT (see
         <a class="local">
          'Euglobulin clot lysis time (ECLT)'
         </a>
         below) or other global assays, such as the plasma clot lysis time or the global thrombosis test (GTT), which have some clinical value in predicting recurrent thrombosis, but their specificity is not high [
         <a href="#rid97">
          97-99
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2477329150">
         <span class="h2">
          Laboratory assays
         </span>
         <span class="headingEndMark">
          —
         </span>
         Laboratory tests for fibrinolysis are discussed below and summarized in the table  (
         <a class="graphic graphic_table graphicRef143848" href="/z/d/graphic/143848.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H10592760">
         <span class="h3">
          Thromboelastography (TEG) and ROTEM
         </span>
         <span class="headingEndMark">
          —
         </span>
         TEG assesses the viscoelastic properties of whole blood, including clot formation and breakdown. TEG measures the torque on a pin dipped into a rotating plastic cup filled with non-anticoagulated whole blood. As a clot begins to form, the torque increases, and with clot breakdown from fibrinolysis, the torque decreases. TEG can be performed at the point of care, such as the operating room or emergency medicine department. Rotational thromboelastometry (ROTEM) is a related assay that also measures clot viscoelastic properties. TEG and ROTEM are considered especially useful in trauma patients and during orthotopic liver transplantation, which are associated with clinically significant excessive fibrinolysis [
         <a href="#rid93">
          93
         </a>
         ].
        </p>
        <p>
         Sample tracings and interpretation are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/15147.html" rel="external">
          "Etiology and diagnosis of coagulopathy in trauma patients", section on 'Viscoelastic hemostatic assays'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Advantages
         </strong>
         – This testing is useful for measuring the magnitude and timing of the fibrinolytic process. Other advantages include the ability to perform the test at the point of care and to repeat it frequently (eg, to monitor the patient's status over time or to determine if interventions have improved various parameters of clot formation and breakdown). TEG also can be used to guide optimal administration of blood products or other therapies [
         <a href="#rid100">
          100
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disadvantages
         </strong>
         – In contrast to clotting assays such as the prothrombin time (PT), there is a lack of standardization of TEG results. Considerable expertise is required for interpretation of results, and there are limited data from clinical studies demonstrating the effectiveness of results in guiding clinical management. Additionally, these tests require fresh blood samples, and they are not available in many clinical laboratories.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3729631179">
         <span class="h3">
          Global thrombosis test (GTT)
         </span>
         <span class="headingEndMark">
          —
         </span>
         The GTT is a point-of-care assay that measures shear-induced clot formation in non-anticoagulated whole blood. The assay also measures the time required for clot lysis to occur. Hence, it is a global assay of platelet function, the blood coagulation system, and the fibrinolytic system, rather than an isolated assay of the fibrinolytic system.
        </p>
        <p>
         Clot lysis time assessed by the GTT is shortened in patients with hyperfibrinolysis and prolonged in patients with impaired fibrinolytic activity [
         <a href="#rid99">
          99,101,102
         </a>
         ]. This test is not available in most clinical laboratories.
        </p>
        <p class="headingAnchor" id="H336356047">
         <span class="h3">
          Euglobulin clot lysis time (ECLT)
         </span>
         <span class="headingEndMark">
          —
         </span>
         The ECLT assesses the global function of the fibrinolytic system.
        </p>
        <p>
         Dilution of citrated plasma at low ionic strength and low pH precipitates the euglobulin fraction, a population of proteins that includes fibrinogen, plasminogen, and tPA but lacks fibrinolysis inhibitors. The proteins in the euglobulin fraction are dissolved in buffer, clotted by addition of thrombin, and the time for clot lysis measured.
        </p>
        <p>
         A shortened ECLT is characteristic of a hyperfibrinolytic state. The presence of a shortened ECLT in the absence of thrombocytopenia and schistocytosis is characteristic of primary hyperfibrinolysis and can be used to help differentiate primary hyperfibrinolysis from DIC and thrombotic thrombocytopenic purpura (TTP)  (
         <a class="graphic graphic_table graphicRef78455" href="/z/d/graphic/78455.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p>
         The ECLT was developed in the 1950s. While still used, it has tended to be replaced by more rapidly performed assays that assess the global function of the fibrinolytic system under more physiologic conditions, such TEG and the GTT. (See
         <a class="local">
          'Thromboelastography (TEG) and ROTEM'
         </a>
         above and
         <a class="local">
          'Global thrombosis test (GTT)'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2347278641">
         <span class="h3">
          Fibrinolytic factor levels
         </span>
         <span class="headingEndMark">
          —
         </span>
         Plasma levels of specific components of the fibrinolytic system can be measured by immunologic and functional assays. Testing is available for:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alpha-2-antiplasmin
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         PAI-1
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         TAFI
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         tPA
        </p>
        <p>
        </p>
        <p>
         These tests are available in some clinical laboratories. If not available locally, they can be performed on frozen citrated plasma samples as a "send-out" test to a specialty laboratory.
        </p>
        <p class="headingAnchor" id="H31">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H10592881">
         <span class="h2">
          Treatment of the underlying disorder
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of abnormal fibrinolysis is initially geared at correcting underlying cause(s).
        </p>
        <p>
         Examples include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cancer
         </strong>
         – If hyperfibrinolysis is secondary to prostate cancer or acute promyelocytic leukemia, successful treatment of the malignancy can restore normal fibrinolytic function. (See
         <a class="medical medical_review" href="/z/d/html/4498.html" rel="external">
          "Initial treatment of acute promyelocytic leukemia in adults", section on 'Control of coagulopathy'
         </a>
         and
         <a class="local">
          'General hyperfibrinolytic states'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Trauma
         </strong>
         – In coagulopathy of trauma, attention to body temperature, pH, and fluid status may reduce the severity of the coagulopathy. (See
         <a class="medical medical_review" href="/z/d/html/15147.html" rel="external">
          "Etiology and diagnosis of coagulopathy in trauma patients"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94347.html" rel="external">
          "Perioperative blood management: Strategies to minimize transfusions", section on 'Maintenance of normothermia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          DIC
         </strong>
         – For disseminated intravascular coagulation (DIC), treatment of causative infections or other underlying causes removes the ongoing stimulus for consumption of clotting factors and generation of fibrin. (See
         <a class="medical medical_review" href="/z/d/html/1306.html" rel="external">
          "Evaluation and management of disseminated intravascular coagulation (DIC) in adults", section on 'Treat the underlying cause'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H10593002">
         <span class="h2">
          Therapies for hyperfibrinolytic states
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fibrinolysis inhibitors, also called antifibrinolytic agents, have been used to treat hyperfibrinolytic states and reduce perioperative blood losses in conditions associated with activation of the fibrinolytic system [
         <a href="#rid103">
          103
         </a>
         ]. (See
         <a class="local">
          'Tranexamic acid and aminocaproic acid'
         </a>
         below and
         <a class="local">
          'Aprotinin'
         </a>
         below.)
        </p>
        <p>
         The use of these agents in patients with liver disease and hyperfibrinolysis is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/13932.html" rel="external">
          "Hemostatic abnormalities in patients with liver disease", section on 'Bleeding'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H32">
         <span class="h3">
          Tranexamic acid and aminocaproic acid
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          Tranexamic acid
         </a>
         (TXA) and
         <a class="drug drug_general" data-topicid="8561" href="/z/d/drug information/8561.html" rel="external">
          aminocaproic acid
         </a>
         (also called epsilon-aminocaproic acid [EACA]) are lysine analogues that bind to the kringle domains of plasminogen and disrupt binding interactions between plasminogen and lysine residues within fibrin. By inhibiting recruitment of plasminogen to the clot surface, these drugs inhibit fibrinolysis. (See
         <a class="local">
          'Fibrinolytic process'
         </a>
         above.)
        </p>
        <p>
         TXA binds plasminogen and plasmin more avidly than
         <a class="drug drug_general" data-topicid="8561" href="/z/d/drug information/8561.html" rel="external">
          aminocaproic acid
         </a>
         does, and TXA may produce a more potent anti-hemorrhagic effect [
         <a href="#rid104">
          104
         </a>
         ].
        </p>
        <p>
         Antifibrinolytic agents have been recommended for use in settings where fibrinolysis is prominent, such as when tissues with high fibrinolytic activity are involved (eg, oropharynx, prostate, endometrium), in selected patients with hemorrhagic shock who have an elevated D-dimer and depleted fibrinogen, and in the coagulopathy of trauma. They are not particularly effective for other types of bleeding, such as from esophageal varices, and they are less effective when given late (more than three hours after bleeding has started) [
         <a href="#rid105">
          105
         </a>
         ]. Viscoelastic testing may be used to assess the presence of hyperfibrinolysis and to guide administration of antifibrinolytic therapy and transfusions.
        </p>
        <p>
         Importantly, disseminated intravascular coagulation (DIC) should be excluded before these agents are administered, since antifibrinolytic therapy can precipitate thrombosis in individuals with DIC. Consequently, DIC is considered a contraindication to the use of antifibrinolytic drugs. (See
         <a class="medical medical_review" href="/z/d/html/1306.html" rel="external">
          "Evaluation and management of disseminated intravascular coagulation (DIC) in adults", section on 'Prevention/treatment of bleeding'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Trauma
         </strong>
         – Major trauma is associated with activation of fibrinolytic pathways, mediated by tissue hypoperfusion and damage of the vascular endothelium, producing a hyperfibrinolytic, prohemorrhagic state [
         <a href="#rid106">
          106
         </a>
         ]. However, a marked inhibition of fibrinolysis is also well recognized in trauma patients, with one study reporting that as many of 64 percent of severely injured patients have "fibrinolytic shutdown" [
         <a href="#rid107">
          107
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         CRASH-2, a randomized trial involving over 10,000 patients, found that early administration of TXA to trauma patients with bleeding or at significant risk of bleeding resulted in a significant reduction in the risk of hemorrhagic death without significantly increasing thrombotic events [
         <a href="#rid108">
          108
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Based on subsequent analyses of the CRASH-2 trial, administration of TXA is recommended in patients with trauma and major hemorrhage if the drug can be administered within three hours of injury, including administration in the field prior to transfer to hospital.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Details of management, including use of antifibrinolytic agents and other therapies, are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15147.html" rel="external">
          "Etiology and diagnosis of coagulopathy in trauma patients"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/117817.html" rel="external">
          "Ongoing assessment, monitoring, and resuscitation of the severely injured patient", section on 'Management of acute traumatic coagulopathy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Liver disease
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/13932.html" rel="external">
          "Hemostatic abnormalities in patients with liver disease", section on 'General approach to managing bleeding'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gynecologic bleeding
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/5415.html" rel="external">
          "Managing an episode of acute uterine bleeding", section on 'Tranexamic acid'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/117.html" rel="external">
          "Abnormal uterine bleeding in adolescents: Management", section on 'Addition of hemostatic therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5476.html" rel="external">
          "Abnormal uterine bleeding in nonpregnant reproductive-age patients: Management", section on 'Nonhormonal therapies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiac surgery
         </strong>
         – TXA has also been studied in patients undergoing cardiovascular surgery [
         <a href="#rid109">
          109
         </a>
         ]. The use of antifibrinolytic agents in patients undergoing coronary artery bypass surgery is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1585.html" rel="external">
          "Early noncardiac complications of coronary artery bypass graft surgery", section on 'Antifibrinolytic agents'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94297.html" rel="external">
          "Blood management and anticoagulation for cardiopulmonary bypass", section on 'Antifibrinolytic administration'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H33">
         <span class="h3">
          Aprotinin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Aprotinin is a 58-amino acid protein isolated from bovine lung that inhibits plasmin, kallikrein, and other proteases. Aprotinin inhibits fibrinolysis, thrombin generation, and inflammatory responses. Due to safety concerns discussed below, it was removed from the market by the US Food and Drug Administration and is not available in the United States.
        </p>
        <p>
         Although aprotinin has been successfully used to reduce blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass during coronary artery bypass grafting surgery, its safety relative to other antifibrinolytic drugs has been called into question. The Blood Conservation Using Antifibrinolytics in a Randomized Trial (BART) randomly assigned 2331 high-risk cardiac surgical patients to receive aprotinin,
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          tranexamic acid
         </a>
         , or
         <a class="drug drug_general" data-topicid="8561" href="/z/d/drug information/8561.html" rel="external">
          aminocaproic acid
         </a>
         [
         <a href="#rid110">
          110
         </a>
         ]. While aprotinin was associated with a reduction in massive bleeding compared with the other two agents, it was also associated with a significantly higher risk of death, which has led to the recommendation that aprotinin not be used to prevent excessive bleeding in cardiac surgery. This subject is discussed in depth separately. (See
         <a class="medical medical_review" href="/z/d/html/1585.html" rel="external">
          "Early noncardiac complications of coronary artery bypass graft surgery", section on 'Antifibrinolytic agents'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1534452109">
         <span class="h2">
          Therapies for hypofibrinolytic states
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypofibrinolytic states are generally treated, if necessary, by downregulating clot formation with an anticoagulant. Indications and choice of drug are discussed in separate topic reviews. (See
         <a class="medical medical_review" href="/z/d/html/13932.html" rel="external">
          "Hemostatic abnormalities in patients with liver disease", section on 'Venous thromboembolism (VTE)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/95336.html" rel="external">
          "Venous thromboembolism: Initiation of anticoagulation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H706603590">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/119328.html" rel="external">
          "Society guideline links: Acquired bleeding disorders"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/119326.html" rel="external">
          "Society guideline links: Rare inherited bleeding disorders"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10593045">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fibrinolytic system
         </strong>
         – Fibrinolysis, the enzymatic dissolution of fibrin clots, is essential for maintaining blood vessel patency and completing the healing process after vascular injury  (
         <a class="graphic graphic_figure graphicRef81428" href="/z/d/graphic/81428.html" rel="external">
          figure 1
         </a>
         ). Fibrinolysis is mediated by plasmin, an enzyme for which synthesis, activity, and clearance are tightly regulated by activators, inhibitors, and other regulatory proteins  (
         <a class="graphic graphic_table graphicRef143854" href="/z/d/graphic/143854.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Overview of the fibrinolytic system'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentations
         </strong>
         – Fibrinolytic disorders, resulting from heritable or acquired abnormalities in the expression of fibrinolytic system components, are rare causes of bleeding or thrombosis, depending on whether they increase or decrease plasmin activity:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Bleeding
         </strong>
         – Hyperfibrinolysis can cause bleeding, typically manifested as delayed bleeding after trauma or surgery or bleeding in the oropharyngeal or gynecologic mucosa or other characteristic sites (peri-umbilical, intramedullary). Causes include excess tissue-type or urinary-type plasminogen activator (tPA or uPA [urokinase]) or deficiencies of alpha-2-antiplasmin, plasminogen activator inhibitor (PAI-1), or thrombin-activatable fibrinolysis inhibitor (TAFI). PAI-1 deficiency is also associated with pregnancy loss. Quebec platelet disorder is a congenital platelet disorder in which tandem duplication of
         <em>
          PLAU
         </em>
         , the gene that encodes uPA, causes excessive production of uPA within platelet alpha granules. (See
         <a class="local">
          'Disorders with excess bleeding'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Thrombosis
         </strong>
         – Hypofibrinolysis can cause thrombosis. Causes include tPA or uPA deficiency or overexpression of PAI-1 or TAFI. (See
         <a class="local">
          'Thrombotic disorders'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pseudomembranes
         </strong>
         – Plasminogen deficiency can cause poor wound healing and formation of fibrin-rich mucosal pseudomembranes. (See
         <a class="medical medical_review" href="/z/d/html/132290.html" rel="external">
          "Plasminogen deficiency"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
         – Generally, an evaluation is pursued if the presentation is suggestive of a fibrinolytic disorder and initial laboratory testing for more common causes of bleeding or thrombosis is unrevealing. (See
         <a class="local">
          'Evaluation for abnormal fibrinolysis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Laboratory testing
         </strong>
         – Hyperfibrinolysis may be associated with normal or prolonged plasma clotting times  (
         <a class="graphic graphic_table graphicRef143848" href="/z/d/graphic/143848.html" rel="external">
          table 2
         </a>
         ). Tests such as the euglobulin clot lysis time (ECLT) or thromboelastography (TEG) may be helpful, although these can be challenging to perform and interpret. Consultation with a specialist is recommended to assist with test selection and interpretation of results. (See
         <a class="local">
          'Laboratory assays'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – The differential diagnosis in an otherwise healthy individual includes von Willebrand disease (VWD), which also causes mucosal bleeding, and factor XIII deficiency, which also causes delayed bleeding. The differential diagnosis in an ill individual includes disseminated intravascular coagulation (DIC) and liver disease. Assessment of the clinical response to antifibrinolytic therapy can also be helpful in diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/1367.html" rel="external">
          "Approach to the adult with a suspected bleeding disorder"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1361.html" rel="external">
          "Overview of the causes of venous thrombosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – Management depends on the cause of the disorder and severity of presentation. Treatment of the underlying cause is important in acquired disorders. (See
         <a class="local">
          'Treatment of the underlying disorder'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hyperfibrinolysis and bleeding
         </strong>
         – Hyperfibrinolytic states with bleeding can be treated with antifibrinolytic agents (
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          tranexamic acid
         </a>
         [TXA] or
         <a class="drug drug_general" data-topicid="8561" href="/z/d/drug information/8561.html" rel="external">
          aminocaproic acid
         </a>
         [epsilon-aminocaproic acid; EACA]) if DIC has been excluded. (See
         <a class="local">
          'Therapies for hyperfibrinolytic states'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hypofibrinolysis and thrombosis
         </strong>
         – Hypofibrinolytic states with thrombosis can be treated with anticoagulation. For plasminogen deficiency, plasminogen replacement therapy can be used. (See
         <a class="local">
          'Therapies for hypofibrinolytic states'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/132290.html" rel="external">
          "Plasminogen deficiency"
         </a>
         .)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol 2005; 129:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 2009; 7:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and future prospects. Blood 2009; 113:2878.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mazar AP. Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin Cancer Res 2008; 14:5649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christiansen VJ, Jackson KW, Lee KN, McKee PA. The effect of a single nucleotide polymorphism on human alpha 2-antiplasmin activity. Blood 2007; 109:5286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zheng Z, Mukhametova L, Boffa MB, et al. Assays to quantify fibrinolysis: strengths and limitations. Communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee on fibrinolysis. J Thromb Haemost 2023; 21:1043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gils A, Declerck PJ. The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors. Thromb Haemost 2004; 91:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horrevoets AJ. Plasminogen activator inhibitor 1 (PAI-1): in vitro activities and clinical relevance. Br J Haematol 2004; 125:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iwaki T, Urano T, Umemura K. PAI-1, progress in understanding the clinical problem and its aetiology. Br J Haematol 2012; 157:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Booth NA, Bennett B, Wijngaards G, Grieve JH. A new life-long hemorrhagic disorder due to excess plasminogen activator. Blood 1983; 61:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aznar J, Estellés A, Vila V, et al. Inherited fibrinolytic disorder due to an enhanced plasminogen activator level. Thromb Haemost 1984; 52:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Humphries JE, Gonias SL, Pizzo SV, Williams ME. Life-long bleeding diathesis: effect of orthotopic liver transplantation. Am J Clin Pathol 1994; 102:816.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saes JL, Schols SEM, van Heerde WL, Nijziel MR. Hemorrhagic disorders of fibrinolysis: a clinical review. J Thromb Haemost 2018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diamandis M, Paterson AD, Rommens JM, et al. Quebec platelet disorder is linked to the urokinase plasminogen activator gene (PLAU) and increases expression of the linked allele in megakaryocytes. Blood 2009; 113:1543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Veljkovic DK, Rivard GE, Diamandis M, et al. Increased expression of urokinase plasminogen activator in Quebec platelet disorder is linked to megakaryocyte differentiation. Blood 2009; 113:1535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blavignac J, Bunimov N, Rivard GE, Hayward CP. Quebec platelet disorder: update on pathogenesis, diagnosis, and treatment. Semin Thromb Hemost 2011; 37:713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diamandis M, Veljkovic DK, Maurer-Spurej E, et al. Quebec platelet disorder: features, pathogenesis and treatment. Blood Coagul Fibrinolysis 2008; 19:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayward CP, Rivard GE. Quebec platelet disorder. Expert Rev Hematol 2011; 4:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paterson AD, Rommens JM, Bharaj B, et al. Persons with Quebec platelet disorder have a tandem duplication of PLAU, the urokinase plasminogen activator gene. Blood 2010; 115:1264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liang M, Soomro A, Tasneem S, et al. Enhancer-gene rewiring in the pathogenesis of Quebec platelet disorder. Blood 2020; 136:2679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frontini M. Breaking barriers: Quebec platelet disorder. Blood 2020; 136:2603.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kufrin D, Eslin DE, Bdeir K, et al. Antithrombotic thrombocytes: ectopic expression of urokinase-type plasminogen activator in platelets. Blood 2003; 102:926.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahr WH, Zheng S, Sheth PM, et al. Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator. Blood 2001; 98:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tracy PB, Giles AR, Mann KG, et al. Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet Factor V deficiency. J Clin Invest 1984; 74:1221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKay H, Derome F, Haq MA, et al. Bleeding risks associated with inheritance of the Quebec platelet disorder. Blood 2004; 104:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayward CP, Rivard GE, Kane WH, et al. An autosomal dominant, qualitative platelet disorder associated with multimerin deficiency, abnormalities in platelet factor V, thrombospondin, von Willebrand factor, and fibrinogen and an epinephrine aggregation defect. Blood 1996; 87:4967.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayward CP. Inherited disorders of platelet alpha-granules. Platelets 1997; 8:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayward CP, Cramer EM, Kane WH, et al. Studies of a second family with the Quebec platelet disorder: evidence that the degradation of the alpha-granule membrane and its soluble contents are not secondary to a defect in targeting proteins to alpha-granules. Blood 1997; 89:1243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stump DC, Taylor FB Jr, Nesheim ME, et al. Pathologic fibrinolysis as a cause of clinical bleeding. Semin Thromb Hemost 1990; 16:260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saito H. Alpha 2-plasmin inhibitor and its deficiency states. J Lab Clin Med 1988; 112:671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams EC. Plasma alpha 2-antiplasmin activity. Role in the evaluation and management of fibrinolytic states and other bleeding disorders. Arch Intern Med 1989; 149:1769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clyne LP, Caldwell AB. Acquired alpha-2 anti-plasmin deficiency secondary to amyloidosis. Thromb Haemost 1987; 58:797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz BS, Williams EC, Conlan MG, Mosher DF. Epsilon-aminocaproic acid in the treatment of patients with acute promyelocytic leukemia and acquired alpha-2-plasmin inhibitor deficiency. Ann Intern Med 1986; 105:873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okajima K, Kohno I, Soe G, et al. Direct evidence for systemic fibrinogenolysis in patients with acquired alpha 2-plasmin inhibitor deficiency. Am J Hematol 1994; 45:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kushimoto S, Shibata Y, Yamamoto Y. Implications of fibrinogenolysis in patients with closed head injury. J Neurotrauma 2003; 20:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Onundarson PT, Haraldsson HM, Bergmann L, et al. Plasminogen depletion during streptokinase treatment or two-chain urokinase incubation correlates with decreased clot lysability ex vivo and in vitro. Thromb Haemost 1993; 70:998.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diéval J, Nguyen G, Gross S, et al. A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1. Blood 1991; 77:528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee MH, Vosburgh E, Anderson K, McDonagh J. Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding. Blood 1993; 81:2357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schleef RR, Higgins DL, Pillemer E, Levitt LJ. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest 1989; 83:1747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minowa H, Takahashi Y, Tanaka T, et al. Four cases of bleeding diathesis in children due to congenital plasminogen activator inhibitor-1 deficiency. Haemostasis 1999; 29:286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fay WP, Shapiro AD, Shih JL, et al. Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med 1992; 327:1729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fay WP, Parker AC, Condrey LR, Shapiro AD. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood 1997; 90:204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iwaki T, Tanaka A, Miyawaki Y, et al. Life-threatening hemorrhage and prolonged wound healing are remarkable phenotypes manifested by complete plasminogen activator inhibitor-1 deficiency in humans. J Thromb Haemost 2011; 9:1200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flevaris P, Khan SS, Eren M, et al. Plasminogen Activator Inhibitor Type I Controls Cardiomyocyte Transforming Growth Factor-β and Cardiac Fibrosis. Circulation 2017; 136:664.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santamaría A, Borrell M, Mateo J, et al. What is the clinical impact of low plasminogen activator inhibitor-1 (PAI-1) activity? A case report and study of the incidence of low PAI-1 antigen in a healthy population. J Thromb Haemost 2007; 5:1565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agren A, Wiman B, Stiller V, et al. Evaluation of low PAI-1 activity as a risk factor for hemorrhagic diathesis. J Thromb Haemost 2006; 4:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tanimura LK, Weddell JA, McKown CG, et al. Oral management of a patient with a plasminogen activator inhibitor (PAI-1) deficiency: case report. Pediatr Dent 1994; 16:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shapiro A. The use of prophylaxis in the treatment of rare bleeding disorders. Thromb Res 2020; 196:590.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bouma BN, Meijers JC. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). J Thromb Haemost 2003; 1:1566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sillen M, Declerck PJ. Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review. Int J Mol Sci 2021; 22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colucci M, Binetti BM, Branca MG, et al. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology 2003; 38:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Broze GJ Jr, Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood 1996; 88:3815.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mosnier LO, Lisman T, van den Berg HM, et al. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration. Thromb Haemost 2001; 86:1035.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grünewald M, Siegemund A, Grünewald A, et al. Paradoxical hyperfibrinolysis is associated with a more intensely haemorrhagic phenotype in severe congenital haemophilia. Haemophilia 2002; 8:768.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cooper DL, Sandler AB, Wilson LD, Duffy TP. Disseminated intravascular coagulation and excessive fibrinolysis in a patient with metastatic prostate cancer. Response to epsilon-aminocaproic acid. Cancer 1992; 70:656.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shariat SF, Roehrborn CG, McConnell JD, et al. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 2007; 25:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           al-Mashhadani SA, Gader AG, al Harthi SS, et al. The coagulopathy of heat stroke: alterations in coagulation and fibrinolysis in heat stroke patients during the pilgrimage (Haj) to Makkah. Blood Coagul Fibrinolysis 1994; 5:731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bouchama A, Bridey F, Hammami MM, et al. Activation of coagulation and fibrinolysis in heatstroke. Thromb Haemost 1996; 76:909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Lloyd L, Jenkins PV, Bell SF, et al. Acute obstetric coagulopathy during postpartum hemorrhage is caused by hyperfibrinolysis and dysfibrinogenemia: an observational cohort study. J Thromb Haemost 2023; 21:862.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schröder L, Hellmund A, Gembruch U, Merz WM. Amniotic fluid embolism-associated coagulopathy: a single-center observational study. Arch Gynecol Obstet 2020; 301:923.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brandt JT. Plasminogen and tissue-type plasminogen activator deficiency as risk factors for thromboembolic disease. Arch Pathol Lab Med 2002; 126:1376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crowther MA, Roberts J, Roberts R, et al. Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study. Thromb Haemost 2001; 85:390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cugno M, Dominguez M, Cabibbe M, et al. Antibodies to tissue-type plasminogen activator in plasma from patients with primary antiphospholipid syndrome. Br J Haematol 2000; 108:871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cugno M, Cabibbe M, Galli M, et al. Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients. Blood 2004; 103:2121.
          </a>
         </li>
         <li class="breakAll">
          Eitzman DT, Fay WP, Ginsburg D. Plasminogen activator inhibitor-1. In: Textbook of Coronary Thrombosis and Thrombolysis, Becker RC (Ed), Kluwer Academic Publishing, Norwell, MA 1997. p.65.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sánchez Miralles A, Reig Sáenz R, Marco Vera P, et al. [Abnormalities in coagulation and fibrinolysis in septic shock with purpura]. An Esp Pediatr 2002; 56:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raaphorst J, Johan Groeneveld AB, Bossink AW, Erik Hack C. Early inhibition of activated fibrinolysis predicts microbial infection, shock and mortality in febrile medical patients. Thromb Haemost 2001; 86:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Westendorp RG, Hottenga JJ, Slagboom PE. Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet 1999; 354:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoekstra T, Geleijnse JM, Schouten EG, Kluft C. Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk. Thromb Haemost 2004; 91:861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Juhan-Vague I, Pyke SD, Alessi MC, et al. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 1996; 94:2057.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tofler GH, Massaro J, O'Donnell CJ, et al. Plasminogen activator inhibitor and the risk of cardiovascular disease: The Framingham Heart Study. Thromb Res 2016; 140:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Song C, Burgess S, Eicher JD, et al. Causal Effect of Plasminogen Activator Inhibitor Type 1 on Coronary Heart Disease. J Am Heart Assoc 2017; 6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bergstein JM, Riley M, Bang NU. Role of plasminogen-activator inhibitor type 1 in the pathogenesis and outcome of the hemolytic uremic syndrome. N Engl J Med 1992; 327:755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang J, Wang C, Chen N, et al. Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and risk of venous thromboembolism: a meta-analysis. Thromb Res 2014; 134:1241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sundquist K, Wang X, Svensson PJ, et al. Plasminogen activator inhibitor-1 4G/5G polymorphism, factor V Leiden, prothrombin mutations and the risk of VTE recurrence. Thromb Haemost 2015; 114:1156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frischmuth T, Hindberg K, Aukrust P, et al. Elevated plasma levels of plasminogen activator inhibitor-1 are associated with risk of future incident venous thromboembolism. J Thromb Haemost 2022; 20:1618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Folsom AR, Cushman M, Heckbert SR, et al. Prospective study of fibrinolytic markers and venous thromboembolism. J Clin Epidemiol 2003; 56:598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hisada Y, Garratt KB, Maqsood A, et al. Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer. Blood Adv 2021; 5:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95:2855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eichinger S, Schönauer V, Weltermann A, et al. Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 2004; 103:3773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meltzer ME, Lisman T, de Groot PG, et al. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 2010; 116:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santamaría A, Oliver A, Borrell M, et al. Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels. Stroke 2003; 34:2387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Folkeringa N, Coppens M, Veeger NJ, et al. Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levels. Thromb Haemost 2008; 100:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meltzer ME, Doggen CJ, de Groot PG, et al. Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men. Blood 2010; 116:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suri MF, Yamagishi K, Aleksic N, et al. Novel hemostatic factor levels and risk of ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study. Cerebrovasc Dis 2010; 29:497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000; 102:1082.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Willeit P, Kiechl S, Kronenberg F, et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. J Am Coll Cardiol 2014; 64:851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009; 361:2518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol 2022; 42:e48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           von Depka M, Nowak-Göttl U, Eisert R, et al. Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood 2000; 96:3364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sofi F, Marcucci R, Abbate R, et al. Lipoprotein (a) and venous thromboembolism in adults: a meta-analysis. Am J Med 2007; 120:728.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dentali F, Gessi V, Marcucci R, et al. Lipoprotein(a) as a Risk Factor for Venous Thromboembolism: A Systematic Review and Meta-analysis of the Literature. Semin Thromb Hemost 2017; 43:614.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Theusinger OM, Wanner GA, Emmert MY, et al. Hyperfibrinolysis diagnosed by rotational thromboelastometry (ROTEM) is associated with higher mortality in patients with severe trauma. Anesth Analg 2011; 113:1003.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Franchini M, Zaffanello M, Mannucci PM. Bleeding Disorders in Primary Fibrinolysis. Int J Mol Sci 2021; 22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heiman M, Gupta S, Shapiro AD. The obstetric, gynaecological and fertility implications of homozygous PAI-1 deficiency: single-centre experience. Haemophilia 2014; 20:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chapin JC, Hajjar KA. Fibrinolysis and the control of blood coagulation. Blood Rev 2015; 29:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Traby L, Kollars M, Eischer L, et al. Prediction of recurrent venous thromboembolism by clot lysis time: a prospective cohort study. PLoS One 2012; 7:e51447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karasu A, Baglin TP, Luddington R, et al. Prolonged clot lysis time increases the risk of a first but not recurrent venous thrombosis. Br J Haematol 2016; 172:947.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Memtsas VP, Arachchillage DRJ, Gorog DA. Role, Laboratory Assessment and Clinical Relevance of Fibrin, Factor XIII and Endogenous Fibrinolysis in Arterial and Venous Thrombosis. Int J Mol Sci 2021; 22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prabhakaran N, Laziuk K, Hammer RD. The utility of thromboelastography and tranexamic acid in plasminogen activator inhibitor deficiency during pregnancy: a rare case report. Blood Coagul Fibrinolysis 2020; 31:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamamoto J, Inoue N, Otsui K, et al. Global Thrombosis Test (GTT) can detect major determinants of haemostasis including platelet reactivity, endogenous fibrinolytic and thrombin generating potential. Thromb Res 2014; 133:919.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suehiro A, Wakabayashi I, Uchida K, et al. Impaired spontaneous thrombolytic activity measured by global thrombosis test in males with metabolic syndrome. Thromb Res 2012; 129:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007; 356:2301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs 1999; 57:1005.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schutgens REG, Lisman T. Tranexamic Acid Is Not a Universal Hemostatic Agent. Hemasphere 2021; 5:e625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madurska MJ, Sachse KA, Jansen JO, et al. Fibrinolysis in trauma: a review. Eur J Trauma Emerg Surg 2018; 44:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore EE, Moore HB, Gonzalez E, et al. Rationale for the selective administration of tranexamic acid to inhibit fibrinolysis in the severely injured patient. Transfusion 2016; 56 Suppl 2:S110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           CRASH-2 trial collaborators, Shakur H, Roberts I, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Myles PS, Smith JA, Forbes A, et al. Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery. N Engl J Med 2017; 376:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fergusson DA, Hébert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 358:2319.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1326 Version 44.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15842654" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Molecular mechanisms of fibrinolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19017261" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : New insights into the molecular mechanisms of the fibrinolytic system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19008457" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : D-dimer antigen: current concepts and future prospects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18794071" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17317851" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The effect of a single nucleotide polymorphism on human alpha 2-antiplasmin activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36759279" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Assays to quantify fibrinolysis: strengths and limitations. Communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee on fibrinolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14983217" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15015963" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Plasminogen activator inhibitor 1 (PAI-1): in vitro activities and clinical relevance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22360729" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : PAI-1, progress in understanding the clinical problem and its aetiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6681588" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : A new life-long hemorrhagic disorder due to excess plasminogen activator.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6543037" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Inherited fibrinolytic disorder due to an enhanced plasminogen activator level.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7801898" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Life-long bleeding diathesis: effect of orthotopic liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29847021" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Hemorrhagic disorders of fibrinolysis: a clinical review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18988861" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Quebec platelet disorder is linked to the urokinase plasminogen activator gene (PLAU) and increases expression of the linked allele in megakaryocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19029443" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Increased expression of urokinase plasminogen activator in Quebec platelet disorder is linked to megakaryocyte differentiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22102275" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Quebec platelet disorder: update on pathogenesis, diagnosis, and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18277131" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Quebec platelet disorder: features, pathogenesis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21495923" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Quebec platelet disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20007542" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Persons with Quebec platelet disorder have a tandem duplication of PLAU, the urokinase plasminogen activator gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32663239" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Enhancer-gene rewiring in the pathogenesis of Quebec platelet disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33270854" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Breaking barriers: Quebec platelet disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12689937" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Antithrombotic thrombocytes: ectopic expression of urokinase-type plasminogen activator in platelets.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11435291" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6480825" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet Factor V deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15026313" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Bleeding risks associated with inheritance of the Quebec platelet disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8652809" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : An autosomal dominant, qualitative platelet disorder associated with multimerin deficiency, abnormalities in platelet factor V, thrombospondin, von Willebrand factor, and fibrinogen and an epinephrine aggregation defect.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16793651" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Inherited disorders of platelet alpha-granules.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9028947" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Studies of a second family with the Quebec platelet disorder: evidence that the degradation of the alpha-granule membrane and its soluble contents are not secondary to a defect in targeting proteins to alpha-granules.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2237447" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Pathologic fibrinolysis as a cause of clinical bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3057093" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Alpha 2-plasmin inhibitor and its deficiency states.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2475079" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Plasma alpha 2-antiplasmin activity. Role in the evaluation and management of fibrinolytic states and other bleeding disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3672434" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Acquired alpha-2 anti-plasmin deficiency secondary to amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3465267" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Epsilon-aminocaproic acid in the treatment of patients with acute promyelocytic leukemia and acquired alpha-2-plasmin inhibitor deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8250008" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Direct evidence for systemic fibrinogenolysis in patients with acquired alpha 2-plasmin inhibitor deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12866815" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Implications of fibrinogenolysis in patients with closed head injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8165625" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Plasminogen depletion during streptokinase treatment or two-chain urokinase incubation correlates with decreased clot lysability ex vivo and in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1899347" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8481516" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2496147" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10754381" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Four cases of bleeding diathesis in children due to congenital plasminogen activator inhibitor-1 deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1435917" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9207454" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21486382" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Life-threatening hemorrhage and prolonged wound healing are remarkable phenotypes manifested by complete plasminogen activator inhibitor-1 deficiency in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28588076" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Plasminogen Activator Inhibitor Type I Controls Cardiomyocyte Transforming Growth Factor-βand Cardiac Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17439631" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : What is the clinical impact of low plasminogen activator inhibitor-1 (PAI-1) activity? A case report and study of the incidence of low PAI-1 antigen in a healthy population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16409470" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Evaluation of low PAI-1 activity as a risk factor for hemorrhagic diathesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8015955" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Oral management of a patient with a plasminogen activator inhibitor (PAI-1) deficiency: case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31420204" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : The use of prophylaxis in the treatment of rare bleeding disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12871292" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33916027" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12830006" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8916945" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11686321" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12410645" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Paradoxical hyperfibrinolysis is associated with a more intensely haemorrhagic phenotype in severe congenital haemophilia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1623480" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Disseminated intravascular coagulation and excessive fibrinolysis in a patient with metastatic prostate cancer. Response to epsilon-aminocaproic acid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17264329" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7865679" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : The coagulopathy of heat stroke: alterations in coagulation and fibrinolysis in heat stroke patients during the pilgrimage (Haj) to Makkah.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8972010" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Activation of coagulation and fibrinolysis in heatstroke.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36696216" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Acute obstetric coagulopathy during postpartum hemorrhage is caused by hyperfibrinolysis and dysfibrinogenemia: an observational cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32157417" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Amniotic fluid embolism-associated coagulopathy: a single-center observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12421144" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Plasminogen and tissue-type plasminogen activator deficiency as risk factors for thromboembolic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11307802" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10792298" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Antibodies to tissue-type plasminogen activator in plasma from patients with primary antiphospholipid syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14630788" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14630788" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11827669" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : [Abnormalities in coagulation and fibrinolysis in septic shock with purpura].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11522001" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Early inhibition of activated fibrinolysis predicts microbial infection, shock and mortality in febrile medical patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10470701" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15116245" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8901651" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26896607" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Plasminogen activator inhibitor and the risk of cardiovascular disease: The Framingham Heart Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28550093" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Causal Effect of Plasminogen Activator Inhibitor Type 1 on Coronary Heart Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1501651" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Role of plasminogen-activator inhibitor type 1 in the pathogenesis and outcome of the hemolytic uremic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25450536" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and risk of venous thromboembolism: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26245493" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Plasminogen activator inhibitor-1 4G/5G polymorphism, factor V Leiden, prothrombin mutations and the risk of VTE recurrence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35289062" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Elevated plasma levels of plasminogen activator inhibitor-1 are associated with risk of future incident venous thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12873656" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Prospective study of fibrinolytic markers and venous thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33496742" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10779431" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14739223" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20385790" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12947154" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18612536" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20413657" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20299790" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Novel hemostatic factor levels and risk of ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10973834" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25169167" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20032323" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Genetic variants associated with Lp(a) lipoprotein level and coronary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34647487" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11071628" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17679133" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Lipoprotein (a) and venous thromboembolism in adults: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28346964" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Lipoprotein(a) as a Risk Factor for Venous Thromboembolism: A Systematic Review and Meta-analysis of the Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21918164" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Hyperfibrinolysis diagnosed by rotational thromboelastometry (ROTEM) is associated with higher mortality in patients with severe trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34209949" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Bleeding Disorders in Primary Fibrinolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24261743" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : The obstetric, gynaecological and fertility implications of homozygous PAI-1 deficiency: single-centre experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25294122" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Fibrinolysis and the control of blood coagulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23240024" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Prediction of recurrent venous thromboembolism by clot lysis time: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26773756" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Prolonged clot lysis time increases the risk of a first but not recurrent venous thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33540604" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Role, Laboratory Assessment and Clinical Relevance of Fibrin, Factor XIII and Endogenous Fibrinolysis in Arterial and Venous Thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31743119" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : The utility of thromboelastography and tranexamic acid in plasminogen activator inhibitor deficiency during pregnancy: a rare case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24613697" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Global Thrombosis Test (GTT) can detect major determinants of haemostasis including platelet reactivity, endogenous fibrinolytic and thrombin generating potential.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21752433" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Impaired spontaneous thrombolytic activity measured by global thrombosis test in males with metabolic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17538089" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Prevention and treatment of major blood loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10400410" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Tranexamic acid: a review of its use in surgery and other indications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34291198" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Tranexamic Acid Is Not a Universal Hemostatic Agent.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28918481" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Fibrinolysis in trauma: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27100746" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Rationale for the selective administration of tranexamic acid to inhibit fibrinolysis in the severely injured patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20554319" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27774838" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18480196" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : A comparison of aprotinin and lysine analogues in high-risk cardiac surgery.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
